Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo and Eli Lilly Halt Prasugrel Trials (Japan)

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo and Eli Lilly have worked together to develop the powerful anti-coagulant prasugrel. However, the results of that study, which included 13,600 patients, have now been thrown into question. On Oct. 24, Daiichi and Lilly announced they were halting two small, related trials. According to company representatives, the two trials were stopped because researchers felt the dosing needed to be tweaked for some populations. The smaller trials were using the same 60 mg initial dose, followed by 10 mg daily doses, as the TRITON trial. Despite this setback, some insiders say there is no need for investor panic. They contend if there was a major safety issue with the drug, trials would have been halted a long time ago. Others argue if there was no need for concern, the companies would not have halted the trials before the TRITON results were announced. If the results do turn out to be negative, it would have a serious impact on the financial projections for both companies. By the time new studies could be conducted, Sanofi-Aventis' Plavix, prasugrel's major competitor, could be available in a generic form, making the drug an extremely tough sell in a market looking to cut drug costs. (Click here for more - May Require Paid Subscription



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts